Veige Healthcare
The new standard in women’s healthcare
Veige Healthcare is focused on designing and marketing better healthcare solutions for women. The company is developing the first hormone-free, topical solution for the relief of the symptoms of Vulvovaginal Atrophy (VVA).
The Need
More than 32 million women in the U.S. experience acute vaginal discomfort due to low estrogen levels resulting from menopause and the treatment of breast cancer. Symptoms include severe
vaginal dryness, pain, irritation and painful sexual relations. Many of these women also suffer embarrassing incontinence.
Existing therapeutic options involve hormone replacement therapy (HRT), which is associated with significant side effects, does not alleviate the problem in 25% of women and in addition cannot be
used by women who are either undergoing active breast cancer treatment or post-breast cancer treatment. The FDA has determined that HRT also causes a significant increase in the
incidence of cardiac events, dementia, stroke, deep vein thrombosis and cancer, requiring a Black Box warning label on all estrogen-containing products, emphasizing the significant health risks.
The Solution
Veige is pioneering a safe, easy to use, non-hormonal topical treatment intended to relieve these life impacting symptoms. Our unique product uses a proprietary synergistic formulation of a unique Hydrocream combined with selected botanicals formulated specifically to activate the natural tissue rehydration process which relieves and restores the vaginal vitality and function while providing soothing relief. The uniquely formulated Hydrocream is protected by a robust patent portfolio.
This topically applied treatment is based on many years of research that have led to a unique formulation including specific botanicals with a strong safety profile. The product is designed to
maximize the therapeutic effect through hydrodynamic modulation of the damaged vaginal tissue to reduce the pain and dryness of the vagina tissue while restoring the vitality and tone of the natural vagina.
The Veige Hydrocream to relieve VVA symptoms is expected to be cleared as a Medical Device via the 510(k) FDA registration process. Veige has sufficient robust clinical trial data to support strong claims and product differentiation. Time projection for completion of this FDA clearance is Q4 2025.
Team
Jonathan Kalman, CEO
Serial entrepreneur, with track record of launching, building, and selling successful businesses.
-
Early investor and board member across early-stage technology companies with a focus on biopharma and medical devices.
-
Three successful M&A transactions to international corporations for amounts ranging from $70M to $1.1BB.
Dr. William Levine, CSO
-
DDS degree with specialty training in Periodontics from Columbia University.
-
Founder of Izun Pharmaceuticals, a biopharmaceutical company specializing in Botanical Medicine.
-
Diplomate of the American Board of Periodontology.
-
Member of Scientific Board of companies focused on Robotic Surgery and Oral Diagnostic technologies.
Les Kraus, CFO
-
CPA with 40+ years of operational and financial experience covering industrial, retail and wholesale businesses.
-
Former CFO of Australia’s largest menswear retailer, where he managed two sale processes to private equity firms.
Dr Amy Rosenbluh, Director of Production & Laboratory Manager
-
Master’s degree from Harvard University and Ph.D. from Tel Aviv University, with post-doctoral fellowships at both Stanford University and the Weizmann Institute.
-
Vast experience in academic research and management, both in academia and in the private sector.
Scientific Advisory Board
Robin Kroll, MD
Dr. Kroll is a recognized leader in women's healthcare. She is a board-certified Gynecologist and Menopause Clinician with special interests in contraception, menopause, and sexual dysfunction. She is Medical Director Emeritus of Women’s Clinical Research Center where she now serves as Consultant/Advisor. Dr. Kroll is a member of numerous professional societies and has been selected by her peers to be included in Best Doctors and has been named in “Top Doctors” by Seattle Magazine. Dr. Kroll has served as a principal investigator for over 300 clinical trials in the field of women’s health and publishes frequently in peer reviewed journals.
​
Dr. Brian Bernick
Dr. Bernick is a multidimensional healthcare executive and entrepreneur with 30 years of clinical medicine experience, primarily in women’s health. Dr. Bernick founded a women’s health company responsible for 3 FDA new drug approvals and a pharmaceutical company exclusively committed to advancing the health of women. Dr. Bernick is recognized by colleagues as one of the leading practitioners of obstetrics & gynecology and has over 100 peer- reviewed publications and presentations of original research and over 70 US and foreign patents focusing on drug therapies and analysis.
​
Prof. Gabriel Nussbaum
​Prof. Nussbaum is a physician researcher and a tenured full professor in the Institute for Biomedical and Oral Research of the Hebrew University of Jerusalem. He began his research career as an MD, PhD student at the Albert Einstein College of Medicine and did his postdoctoral work at the Weizmann Institute of Science. Prof. Nussbaum trained in internal medicine and conducts research at the interface of inflammation, the host response to microbial pathogens, and cancer.
Contact us
Corporate Headquarters
1177 6th Avenue
5th floor
New York, NY 10036
1-800-580-4387
R&D Headquarters
11 Kiryat Mada Street
3rd floor
Har Hotzvim, Jerusalem 9777611
972-72-245-8950